At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 9,901 enrolled
Drug / intervention
Dulaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)
In Brief
A Phase 3 clinical trial evaluating Dulaglutide and Placebo for Cardiovascular Disease and Diabetes Mellitus, Type 2. Completed, enrolled 9,901 participants across 300 sites in 25 countries.
Detailed Summary
The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease, Diabetes Mellitus, Type 2
CountriesArgentina, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Germany, Hungary, Latvia, Lithuania, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartJul 2011
Primary CompletionAug 2018
TodayJul 2026
First PostedJul 15, 2011
Enrollment StartJul 22, 2011
Primary CompletionAug 21, 2018
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 15.0 years ago
Interventions
Dulaglutidedrug
Administered subcutaneously
Placebodrug
Administered subcutaneously